Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

3.1.15.1: venom exonuclease

This is an abbreviated version!
For detailed information about venom exonuclease, go to the full flat file.

Word Map on EC 3.1.15.1

Reaction

Exonucleolytic cleavage in the 3'- to 5'- direction to yield nucleoside 5'-phosphates =

Synonyms

3'-exonuclease, 5'-exonuclease, 5'-nucleotide phosphodiesterase, alkaline phosphodiesterase, autotaxin, Crotalus adamenteus venom exonuclease, PDE, PDE-I, posphodiesterase I, snake venom phosphodiesterase, snake venom phosphodiesterase I, snake venom phosphodiesterase-I, SVP, SVPD, SVPDE, TS-PDE, venom exonuclease I, venom PDE-I, venom phosphodiesterase, venom phosphodiesterase I, VLPDE

ECTree

     3 Hydrolases
         3.1 Acting on ester bonds
             3.1.15 Exonucleases that are active with either ribo- or deoxyribonucleic acids and produce 5'-phosphomonoesters
                3.1.15.1 venom exonuclease

Inhibitors

Inhibitors on EC 3.1.15.1 - venom exonuclease

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
1,10-phenanthroline
-
-
2-([4-deoxy-4-(hydroxymethyl)-3-O-(phenylcarbonyl)-beta-D-glucopyranosyl]oxy)-5-hydroxybenzyl benzoate
-
IC50: 0.171 mM
2-([4-deoxy-4-(hydroxymethyl)-beta-D-glucopyranosyl]oxy)-5-hydroxybenzyl benzoate
-
IC50: 0.544 mM
2-mercaptoethanol
-
10 mM, 20% of inhibition
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)((E)-2-phenylethenyl)methyl]-2H-chromen-2-one
-
-
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(1H-indol-2-yl)methyl]-2H-chromen-2-one
-
-
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(1H-pyrol-2-yl)methyl]-2H-chromen-2-one
-
-
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(2-bromophenyl)methyl]-2H-chromen-2-one
-
-
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(2-chlorophenyl)methyl]-2H-chromen-2-one
-
-
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(2-methoxyphenyl)methyl]-2H-chromen-2-one
-
-
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(2-pyridinyl)methyl]-2H-chromen-2-one
-
-
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(2-thienyl)methyl]-2H-chromen-2-one
-
-
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(3,4,5-trimethoxyphenyl)methyl]-2H-chromen-2-one
-
-
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(3,4-dimethoxyphenyl) methyl]-2H-chromen-2-one
-
-
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(3-aminophenyl)methyl]-2H-chromen-2-one
-
-
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(3-chlorophenyl)methyl]-2H-chromen-2-one
-
-
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(3-ethoxyphenyl)methyl]-2H-chromen-2-one
-
-
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(3-hydroxyphenyl)methyl]-2H-chromen-2-one
-
-
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(3-methoxyphenyl)methyl]-2H-chromen-2-one
-
-
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(3-nitrophenyl)methyl]-2H-chromen-2-one
-
-
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(3-pyridinyl)methyl]-2H-chromen-2-one
-
-
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(3-thienyl)methyl]-2H-chromen-2-one
-
-
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(4-hydroxy-3-ethoxyphenyl) methyl]-2H-chromen-2-one
-
-
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(4-isopropylphenyl)methyl]-2H-chromen-2-one
-
-
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(4-methoxyphenyl)methyl]-2H-chromen-2-one
-
-
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(4-N,N-dimethylaminophenyl) methyl]-2H-chromen-2-one
-
-
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(4-nitrophenyl)methyl]-2H-chromen-2-one
-
-
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(4-pyridinyl)methyl]-2H-chromen-2-one
-
-
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)ethyl]-2H-chromen-2-one
-
-
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)methyl]-2H-chromen-2-one
-
-
8-Hydroxy-5-quinoline sulfonic acid
-
-
ADP
-
competitive inhibition
benzoyl salireposide
-
shows strong inhibitory activity
Cu2+
-
required for activity, but inhibitory at 1 mM, two Cu2+ binding sites. Cu2+ ions function as a switch for its phosphodiesterase activity
CuSO4
-
10 mM, 90% of inhibition
cysteine
dimerized thymine
dipicolinic acid
-
-
dithiothreitol
-
inhibits the phosphodiesterase activity of the enzyme by reducing both the Cu2+ and disulfide bonds
glutathione
L-ascorbate
-
endogenous inhibitor, inhibits the phosphodiesterase activity of the enzyme through reduction of Cu2+
L-cysteine
-
-
MgSO4
-
100 mM, 40% of inhibition
MnCl2
-
10 mM, 50% of inhibition
o-phenanthroline
-
-
polyclonal antibodies
-
-
-
quinovic acid
snake
-
50% inhibition at 0.166 mM
quinovic acid 3-O-(beta-D-glucopyranoside)
snake
-
50% inhibition at 0.374 mM
quinovic acid-3-O-alpha-L-rhamnopyranoside
-
significant inhibitory activity against the enzyme
quinovic acid-3-O-beta-D-fucopyranoside
-
significant inhibitory activity against the enzyme
quinovic acid-3-O-beta-D-glucopyranosyl (1-> 4)-beta-D-fucopyranoside
-
significant inhibitory activity against the enzyme
salireposide
-
shows moderate inhibitory activity
symplomoside
-
shows weak inhibitory activity
symploracemoside
-
shows moderate inhibitory activity
thioglycolic acid
-
-
tris(2-carboxyethyl)phosphine
-
inhibits the phosphodiesterase activity of the enzyme by reducing both the Cu2+ and disulfide bonds
additional information
-
calf intestine alkaline phosphatase-independent SVPD termini are piperidine resistant
-